BioSpace News Archive

Integer Holdings Corporation, a leading medical device outsource manufacturer, announced results for the three months ended September 29, 2023.

BioVie Inc. today announced that clinical safety data from the Company’s Phase 2 open-label study evaluating the efficacy and safety of BIV201, will be highlighted in a late-breaking poster presentation at The American Association for the Study of Liver Diseases (AASLD) - The Liver Meeting® 2023, taking place from November 10-14, 2023 in Boston, MA.

Theratechnologies Inc. announced that it has priced its previously announced public offering of 12,500,000 common shares of the Company at a public offering price of US$1.00 per Common Share.

INOVIO today announced that third quarter 2023 financial results will be released after the market close on November 9, 2023.

Semaphore Solutions, an innovative leader in laboratory informatics services and LIMS, is delighted to join forces with LinusBio, a pioneer in precision exposome sequencing.

Boston Scientific Corporation generated net sales of $3.527 billion during the third quarter of 2023, growing 11.2 percent on a reported basis, 11.1 percent on an operational1 basis and 10.2 percent on an organic2 basis, all compared to the prior year period.

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company announced further alignment with the FDA Division of Anesthesiology, Addiction Medicine, and Pain Medicine in connection with the development of NRX-101 for treatment of Chronic Pain.

NeuroMetrix, Inc. reported business and financial highlights for the quarter and nine month period ended September 30, 2023.

BioCryst Pharmaceuticals, Inc. announced the enrollment of the first patient in a proof-of-concept clinical trial evaluating BCX10013, a potential once-daily, oral Factor D inhibitor for the treatment of complement-mediated diseases.

Lipocine Inc. announced the completion of a meeting with the FDA and guidance for the appropriate acceptance criteria for the upcoming LPCN 1154 pivotal study.